HRQoL improves in treatment-naïve HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC)

por Baran, RW, Dietz, B, Fredrick, LM, Tian, M, Podsadecki, T
Publicado 2010

Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1

por Maroldo, L, Fredrick, LM, Robinson-Morgan, K, Trinh, R, Podsadecki, TJ
Publicado 2010

Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT‐450, Ombitasvir, and Dasabuvir

por Badri, P., Dutta, S., Coakley, E., Cohen, D., Ding, B., Podsadecki, T., Bernstein, B., Awni, W., Menon, R.
Publicado 2015

Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir

por Krishnan, Preethi, Tripathi, Rakesh, Schnell, Gretja, Reisch, Thomas, Beyer, Jill, Irvin, Michelle, Xie, Wangang, Larsen, Lois, Cohen, Daniel, Podsadecki, Thomas, Pilot-Matias, Tami, Collins, Christine
Publicado 2015

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir

por Badri, Prajakta S., Dutta, Sandeep, Wang, Haoyu, Podsadecki, Thomas J., Polepally, Akshanth R., Khatri, Amit, Zha, Jiuhong, Chiu, Yi-Lin, Awni, Walid M., Menon, Rajeev M.
Publicado 2015

Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers...

por Polepally, Akshanth R., King, Jennifer R., Ding, Bifeng, Shuster, Diana L., Dumas, Emily O., Khatri, Amit, Chiu, Yi-Lin, Podsadecki, Thomas J., Menon, Rajeev M.
Publicado 2016